期刊
CANCER JOURNAL
卷 19, 期 6, 页码 511-516出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0000000000000007
关键词
Cancer; inflammation; immunogenic cell death; dendritic cells; T(H)2
类别
资金
- BIIR
- Baylor University Medical Center Foundation
- Baylor Sammons Cancer Center
- Susan B. Komen Foundation
- Cancer Prevention Research Institute of Texas
- NIH/NCI
- Susan B Komen Foundation
- Dept of Defense Breast Cancer Research Program
- Breast Cancer Research Foundation
Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells? Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据